<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650581</url>
  </required_header>
  <id_info>
    <org_study_id>MA40</org_study_id>
    <nct_id>NCT04650581</nct_id>
  </id_info>
  <brief_title>Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor</brief_title>
  <acronym>FINER</acronym>
  <official_title>A Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth&#xD;
      of advanced breast cancer when added to standard therapy (Fulvestrant).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients enrolled in this study will receive either Ipatasertib plus Fulvestrant or placebo&#xD;
      (a substance that looks like the study drug but does not have any active or medicinal&#xD;
      ingredient) plus Fulvestant. The study will provide information about the ability of&#xD;
      Ipatasertib plus Fulvestrant to control the cancer, the side effects and safety of the&#xD;
      treatment, how patients feel while taking the treatment and associated costs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) using RECIST 1.1</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the two treatment arms with respect to investigator assessed PFS (per RECIST 1.1) in the PIK3CA/AKT1/PTEN altered cohort</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessed PFS (per RECIST 1.1) in the PIK3CA/AKT1/PTEN non-altered cohort</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS as assessed by blinded central radiology review in all enrolled patients, PIK3CA/AKT1/PTEN altered and non-altered cohorts</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR) (per RECIST 1.1)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR);</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to commencement of subsequent line of systemic therapy or death (TSST)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) as measured using EORTC QLQ-C30 questionnaire</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events as measured using NCI PRO-CTCAE questionnaire</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic Evaluation of healthcare utilization using average cost per study subject by treatment arm to estimate an overall mean cost per study arm.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic Evaluation of health utilities measured using EQ-5D-5L</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Ipatasertib + Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib</intervention_name>
    <description>400 mg PO QD days 1-21 every 28 days</description>
    <arm_group_label>Ipatasertib + Fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles</description>
    <arm_group_label>Ipatasertib + Fulvestrant</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PO QD days 1-21 every 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically and/or cytologically confirmed ER positive, HER-2 negative breast&#xD;
             cancer&#xD;
&#xD;
          -  Female patients must be post-menopausal; female patients who are pre-menopausal must&#xD;
             have ovarian suppression using LHRH agonist while on study&#xD;
&#xD;
          -  Clinical and/or radiographic progression during treatment with or within 28 days after&#xD;
             discontinuation of first line of treatment with a CDK 4/6 inhibitor and an aromatase&#xD;
             inhibitor (AI) for advanced/metastatic disease&#xD;
&#xD;
          -  Evidence of clinically and/or radiologically documented disease&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  No concurrent anti-cancer therapy and must satisfy the following criteria for previous&#xD;
             therapy&#xD;
&#xD;
               -  Must not have received more than one prior line of treatment with a CDK 4/6&#xD;
                  inhibitor and an AI in the advanced disease setting.&#xD;
&#xD;
               -  Treatment with CDK 4/6 inhibitor and AI must have been the most recent treatment&#xD;
                  prior to registration for this study&#xD;
&#xD;
          -  Adequate hematology and organ function, in the absence of growth factors&#xD;
&#xD;
               -  Absolute neutrophils &gt; 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Hemoglobin &gt; 90 g/L&#xD;
&#xD;
               -  Total Bilirubin ≤ 1.5 x ULN (upper limit of normal) or ≤ 3 x ULN if confirmed&#xD;
                  Gilbert's Syndrome&#xD;
&#xD;
               -  ALT and AST ≤ 2.5 x ULN (or ≤ 5.0 x ULN if liver or bone metastasis)&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.0 x ULN (or ≤ 5.0 x ULN if liver metastases, ≤ 7.0 x ULN&#xD;
                  if bone metastasis)&#xD;
&#xD;
               -  Fasting glucose ≤ 8.3 mmol/L&#xD;
&#xD;
               -  HbA1c ≤ 7.5%&#xD;
&#xD;
               -  Serum albumin ≥ 30 g/L&#xD;
&#xD;
               -  INR ≤ 1.2&#xD;
&#xD;
               -  Serum Creatinine or Creatinine clearance ≤ 1.5 x ULN or ≥ 50 mL/min; measured&#xD;
                  directly by 24-hour urine sampling or as calculated by Crockcroft and Gault&#xD;
                  equation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated or symptomatic CNS metastases, radiation treatment for CNS metastases within&#xD;
             28 days&#xD;
&#xD;
          -  Active inflammatory bowel disease, bowel inflammation, inability to swallow oral&#xD;
             medication or GI condition that alters oral absorption&#xD;
&#xD;
          -  Prior treatment with fulvestrant, selective estrogen receptor degraders (SERDs) or&#xD;
             known inhibitors of the PI3K pathway including PI3K inhibitors, AKT inhibitors, or&#xD;
             mTOR inhibitors&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate (QTc) ≥ 480 msec by ECG or history of&#xD;
             familial long QT syndrome&#xD;
&#xD;
          -  Active or uncontrolled infections or serious illnesses or medical conditions&#xD;
&#xD;
          -  Clinically significant liver diseases&#xD;
&#xD;
          -  History of lung disease or history of opportunistic infections&#xD;
&#xD;
          -  Type 1 or Type 2 diabetes mellitus requiring insulin&#xD;
&#xD;
          -  Grade ≥ 2 uncontrolled hypercholesterolemia or hypertriglyceridemia&#xD;
&#xD;
          -  Known abnormalities in coagulation&#xD;
&#xD;
          -  History of hypersensitivity to the study drugs or components&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Chia</last_name>
    <role>Study Chair</role>
    <affiliation>BCCA - Vancouver Cancer Centre, BC Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy Parulekar</last_name>
    <phone>613-533-6430</phone>
    <email>wparulekar@ctg.queensu.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>BCCA - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Kristina Taylor</last_name>
      <phone>250 712-3996</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Chan</last_name>
      <phone>604 930-4060</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Chia</last_name>
      <phone>604 877-6000</phone>
      <phone_ext>2752</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Regional Health Authority B, Zone 2</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margot Burnell</last_name>
      <phone>506 648-6884</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Singh</last_name>
      <phone>705 728-9090</phone>
      <phone_ext>43560</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juhi Husain</last_name>
      <phone>905 494-2120</phone>
      <phone_ext>572643</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nidhi Kumar Tyagi</last_name>
      <phone>905 387-9495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Antoun Raphael</last_name>
      <phone>519 685-8640</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oak Valley Health</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 7P3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikaash Kumar</last_name>
      <phone>905 472-7072</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stronach Regional Health Centre at Southlake</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin H. Rahim</last_name>
      <phone>905 895-4521</phone>
      <phone_ext>6596</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Ng</last_name>
      <phone>613 737-7700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Voutsadakis</last_name>
      <phone>705 759-3434</phone>
      <phone_ext>4450</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cescon</last_name>
      <phone>416 946-2245</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amin Kay</last_name>
      <phone>519 253-5253</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUM-Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Ayoub</last_name>
      <phone>514 890-8000</phone>
      <phone_ext>20692</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHA-Hopital Du St-Sacrement</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Desbiens</last_name>
      <phone>418 682-7511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haji Ibrahim Chalchal</last_name>
      <phone>306 766-2691</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amer Sami</last_name>
      <phone>306 655-2710</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

